Havn Life Sciences Signs LOI to Research and Develop Medical Psilocybin with Jamaican Company Hypha Wellness
Havn Life believes operations can advance its business plan and potentially accelerate production of naturally-derived psilocybin for global medical research.
Havn Life Sciences Inc. (CNSX: HAVN) (OTCMKTS: HAVLF), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, has entered into a letter of intent (LOI) with nutraceutical company Hypha Wellness Jamaica Psilocybin (HWJP) towards jointly researching and, subject to compliance with all applicable laws and regulations, producing standardized powdered homogenizedpsilocybin mushroom active pharmaceutical ingredient (API) products.
Headquartered in Kingston, HWJP is focused on the cultivation, extraction, and manufacturing of nutraceuticals. They are uniquely positioned to explore and optimise the therapeutic and commercial potentials of psilocybin and other fungi for local and international markets. This collaboration is expected to further Havn Life’s goal of developing a supply chain for regulated production of medical psilocybin. Working with Veterans and thought leaders in the military [NTD: ensure this statement is still accurate re working with Veterans], Havn Life is developing innovative formulations to support future clinical trials addressing PTSD recovery and other trauma related disorders, empowering people to connect to their potential and thrive.
Havn Life also notes that it is developing a production facility in Jamaica to produce psychedelic mushroom API. The Company is also actively engaged in pursuing additional opportunities to collaborate with the scientific and business communities in Jamaica.
Havn Life believes that setting up operations in Jamaica will advance the Company’s ability to optimize standardized quality controlled production methods for naturally-derived psilocybin, accelerating its overall business plan. Collaborating with HWJP also brings local knowledge and insight to the Company’s operation, potentially paving the way towards the development of functional standards across the industry.
Growing regulated psilocybin mushrooms for medical research is a very complex process. Our Jamaican collaborations are expected to allow us to optimize and refine our processes faster than we could elsewhere. Most importantly, they’re expected to better facilitate Havn Life’s commitment to helping patients, specifically those participating in observational studies in Jamaica. Havn Life’s work in Jamaica is aimed at furthering our mandate of supplying safe, quality controlled, psilocybin medicine to researchers and patients around the globe. We want to supply as many researchers as we can with naturally derived compounds and this partnership will bring us one step closer to our goal of building an international psychedelic supply chain framework.Dr. Ivan Casselman, Chief Psychedelic Officer of Havn Life.
For HWJP, the partnership represents a major milestone in its work toward facilitating industry growth and building an innovative framework for creating and distributing Jamaican nutraceuticals and pharmaceuticals across the island and around the world.
To view the press release in its entirety click here